Immix Biopharma (IMMX) News Today

HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Friday.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 557,400 shares, an increase of 17.8% from the June 15th total of 473,100 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average daily volume of 147,700 shares, the days-to-cover ratio is presently 3.8 days.

HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Immix Biopharma in a research note on Tuesday.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 473,100 shares, a growth of 39.7% from the May 31st total of 338,700 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily trading volume, of 131,400 shares, the days-to-cover ratio is presently 3.6 days.

HC Wainwright assumed coverage on shares of Immix Biopharma in a report on Monday. They issued a "buy" rating and a $7.00 price target on the stock.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 338,700 shares, a decline of 7.6% from the May 15th total of 366,500 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average daily volume of 134,900 shares, the short-interest ratio is currently 2.5 days.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 366,500 shares, a drop of 5.4% from the April 30th total of 387,500 shares. Based on an average daily volume of 162,300 shares, the short-interest ratio is currently 2.3 days. Currently, 2.4% of the shares of the company are short sold.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 387,500 shares, a growth of 10.7% from the April 15th total of 349,900 shares. Based on an average daily trading volume, of 204,300 shares, the short-interest ratio is currently 1.9 days. Currently, 2.8% of the shares of the company are short sold.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) CFO Gabriel S. Morris acquired 4,500 shares of the firm's stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $2.23 per share, with a total value of $10,035.00. Following the completion of the transaction, the chief financial officer now directly owns 85,816 shares in the company, valued at approximately $191,369.68. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 349,900 shares, a drop of 10.0% from the March 31st total of 388,800 shares. Currently, 2.5% of the company's shares are short sold. Based on an average daily volume of 278,000 shares, the days-to-cover ratio is currently 1.3 days.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 212,900 shares, a growth of 52.3% from the December 15th total of 139,800 shares. Based on an average daily volume of 258,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.8% of the shares of the company are short sold.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 212,900 shares, an increase of 52.3% from the December 15th total of 139,800 shares. Based on an average trading volume of 258,000 shares, the short-interest ratio is presently 0.8 days. Approximately 2.8% of the shares of the company are short sold.